

PANCREATIC CANCER RESEARCH IN EUROPE

Multistakeholder Brainstorming Meeting

Wednesday 12 April 2017

Restaurant I LATINI – 2 place Ste Catherine, Brussels 1000

PANCREATIC CANCER RESEARCH PRIORITIES IN EUROPE

- 12:00 – 12:30 **Welcome and introduction of participants and the meeting.**
Dr Núria Malats, Spanish National Cancer Research Centre (CNIO), Madrid.
- 13:30 – 14:00 **Discussion Block 1 Topics: Defining a pancreatic cancer high-risk population for primary and secondary (screening) prevention.**
Dr Núria Malats, Spanish National Cancer Research Centre (CNIO), Madrid.
- 14:00 – 14:30 **Discussion Block 2 Topics: Identifying and validating markers/tests for early diagnosis.**
Prof Matthias Löhr, Karolinska Institutet, Stockholm.
- 14:30 – 15:00 **Discussion Block 3 Topics: Searching for efficient treatments for PC.**
Chair
- 15:00 – 15:30 **Discussion Block 4 Topics: Actions to be conducted/invested on pancreatic cancer research in Europe.**
Chair
- 15:30 – 15:50 **Funding opportunities in H2020 new calls**
Dr Dominika Trzaska, European Commission, Unit E4.
- 15:50 – 16:00 **Meeting wrap-up and conclusion**
Dr Núria Malats, Spanish National Cancer Research Centre (CNIO), Madrid.

PANCREATIC CANCER RESEARCH IN EUROPE
Multistakeholder Brainstorming Meeting
Wednesday 12 April 2017
Restaurant I LATINI – 2 place Ste Catherine, Brussels 1000

Points to guide the discussion during the meeting

Block 1. Main topics to address in pancreatic cancer research: Defining a pancreatic cancer high-risk population for primary and secondary (screening) prevention.

* In grey, key points taken by the U.S. Congress "Pancreatic Cancer Research and Education Act"

Conductor: Núria Malats, Spanish National Cancer Research Centre (CNIO), Madrid.

1. Focusing on the 90% sporadic PC, while also considering FPC/HPC (10%)
2. Integrating established risk factors with biomarkers (omics) towards a "personalized prevention" of PC
3. Exploring the role of microbiome in PC risk and prevention
4. Understanding the biological relationship between diabetes mellitus and PC (US RCR Act 2014)
5. Diagnosing and accurately classifying precursor lesions (cystic tumours, IPMN, and PanINs) according to imaging (MRI) features and biomarkers
6. Others

Block 2. Main topics to address in pancreatic cancer research: Identifying and validating markers/tests for early diagnosis.

* In grey, key points taken by the U.S. Congress "Pancreatic Cancer Research and Education Act"

Conductor: Matthias Löhr, Karolinska Institutet, Stockholm

1. Defining the real "window of opportunity" for PC screening
2. Understanding the catastrophic progression of PC
3. Evaluating screening protocols for biomarkers for early detection of pancreatic cancer and its precursors (US RCR Act 2014)
4. Listing and prioritizing biomarkers, upon the availability of evidences, for their validation in well-characterized common resources (population, samples, data)
5. Estimating cost/efficient screening interventions in high-risk populations
6. Others

PANCREATIC CANCER RESEARCH IN EUROPE
Multistakeholder Brainstorming Meeting
Wednesday 12 April 2017
Restaurant I LATINI – 2 place Ste Catherine, Brussels 1000

Block 3. Main topics to address in pancreatic cancer research: Searching for efficient treatments for PC.

* In grey, key points taken by the U.S. Congress "Pancreatic Cancer Research and Education Act"

Conductor:

1. Identifying markers for response prediction towards PC "personalized treatment"
2. Exploring the effect of combinatorial therapeutic schemes in PC survival including radiotherapy, surgery, immunotherapy, and standard/new chemotherapy drugs
3. Studying new therapeutic strategies in immunotherapy
4. Developing new treatment approaches that interfere with RAS-oncogene signalling pathway (US RCR Act 2014)
5. Identifying synthetic lethality combinatorial approaches leading to PC extinction
6. Exploring the role of cachexia and its metabolic pathways in PC progression and treatment opportunities
7. Understanding the impact of aging and co-morbidity processes in PC progression and treatment opportunities
8. Identifying prognostic markers for PC
9. Searching for second-line chemotherapy drugs for PC patient management



PANCREATIC CANCER RESEARCH IN EUROPE
Multistakeholder Brainstorming Meeting
Wednesday 12 April 2017
Restaurant I LATINI – 2 place Ste Catherine, Brussels 1000

Block 4. Actions to be conducted/invested on pancreatic cancer research in Europe

Conductor:

1. Strengthening the application of a "systems thinking" approach
2. Supporting long-term investment
3. Establishing multistakeholder cooperative teams including multidisciplinary research and health professional teams, private sector representatives, patients, health economics professionals, and policy makers
4. Conducting EU large (huge) standardized (ongoing) epidemiological studies linked to clinical annotated biobanks. Apply novel "smart" technologies to characterize exposures.
5. Building large cohorts of high-risk populations (new-onset diabetes mellitus, PC precursors: IPMN and PanINs) with detailed information and annotated biobank
6. Networking with already established registries of Familial/Hereditary Pancreas Cancer linked to family-based biobanks
7. Promoting cooperative work through the collection of longitudinal data and sample collection (PancreOS + Biobank) linked to e-medical records
8. Building large well annotated (clinical-pathological-follow up) biobank network applying the same procedures (SOP)
9. Standardizing omics data generation and next-generation database platforms. Developing algorithms allowing omics and non-omics data integration. Fostering Quantum-computing